Perspectives in using gene therapy for lysosomal storage diseases

S. P. Sloniowski, J. C. Fox, S. J. Gray

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Conceptually, lysosomal storage disorders (LSDs) are highly amenable to gene transfer therapies because they are monogenic and most of them can benefit from cross-correction. However, past gene transfer clinical trials for LSDs, utilizing focal delivery approaches to the brain for Batten disease and Canavan disease, have provided minimal therapeutic benefit to patients. Recent advancements in vector technology now allow for broad central nervous system and/or peripheral organ gene transfer via in vivo and ex vivo approaches, and the application of these technologies has shown considerable promise in small and large animal preclinical studies. Innate and adaptive immune responses pose a risk for the safety and efficacy of gene transfer in some human populations. This review discusses recent gene therapy advancements, other treatment options, and the risks and obstacles associated with the different therapeutic approaches for LSDs. The objective is to provide an introductory summary of where the field of gene therapy currently stands in the treatment of LSDs, and the directions the field is moving toward. Based on results in animal models, global gene transfer has the potential to profoundly alter the course of LSDs. Moreover, these newer approaches are scalable to large animals and presumably humans.

Original languageEnglish (US)
Pages (from-to)635-643
Number of pages9
JournalDrugs of the Future
Volume38
Issue number9
DOIs
StatePublished - Jan 1 2013

Fingerprint

Lysosomal Storage Diseases
Genetic Therapy
Genes
Canavan Disease
Neuronal Ceroid-Lipofuscinoses
Technology
Brain Diseases
Adaptive Immunity
Therapeutics
Innate Immunity
Central Nervous System
Animal Models
Clinical Trials
Safety
Population

Keywords

  • Adeno-associated virus
  • Central nervous system
  • Gene therapy
  • Lentivirus
  • Lysosomal storage disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Perspectives in using gene therapy for lysosomal storage diseases. / Sloniowski, S. P.; Fox, J. C.; Gray, S. J.

In: Drugs of the Future, Vol. 38, No. 9, 01.01.2013, p. 635-643.

Research output: Contribution to journalArticle

Sloniowski, S. P. ; Fox, J. C. ; Gray, S. J. / Perspectives in using gene therapy for lysosomal storage diseases. In: Drugs of the Future. 2013 ; Vol. 38, No. 9. pp. 635-643.
@article{9f0719d7db5c4cc699f11eff479e64f9,
title = "Perspectives in using gene therapy for lysosomal storage diseases",
abstract = "Conceptually, lysosomal storage disorders (LSDs) are highly amenable to gene transfer therapies because they are monogenic and most of them can benefit from cross-correction. However, past gene transfer clinical trials for LSDs, utilizing focal delivery approaches to the brain for Batten disease and Canavan disease, have provided minimal therapeutic benefit to patients. Recent advancements in vector technology now allow for broad central nervous system and/or peripheral organ gene transfer via in vivo and ex vivo approaches, and the application of these technologies has shown considerable promise in small and large animal preclinical studies. Innate and adaptive immune responses pose a risk for the safety and efficacy of gene transfer in some human populations. This review discusses recent gene therapy advancements, other treatment options, and the risks and obstacles associated with the different therapeutic approaches for LSDs. The objective is to provide an introductory summary of where the field of gene therapy currently stands in the treatment of LSDs, and the directions the field is moving toward. Based on results in animal models, global gene transfer has the potential to profoundly alter the course of LSDs. Moreover, these newer approaches are scalable to large animals and presumably humans.",
keywords = "Adeno-associated virus, Central nervous system, Gene therapy, Lentivirus, Lysosomal storage disease",
author = "Sloniowski, {S. P.} and Fox, {J. C.} and Gray, {S. J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1358/dof.2013.038.09.2038787",
language = "English (US)",
volume = "38",
pages = "635--643",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Perspectives in using gene therapy for lysosomal storage diseases

AU - Sloniowski, S. P.

AU - Fox, J. C.

AU - Gray, S. J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Conceptually, lysosomal storage disorders (LSDs) are highly amenable to gene transfer therapies because they are monogenic and most of them can benefit from cross-correction. However, past gene transfer clinical trials for LSDs, utilizing focal delivery approaches to the brain for Batten disease and Canavan disease, have provided minimal therapeutic benefit to patients. Recent advancements in vector technology now allow for broad central nervous system and/or peripheral organ gene transfer via in vivo and ex vivo approaches, and the application of these technologies has shown considerable promise in small and large animal preclinical studies. Innate and adaptive immune responses pose a risk for the safety and efficacy of gene transfer in some human populations. This review discusses recent gene therapy advancements, other treatment options, and the risks and obstacles associated with the different therapeutic approaches for LSDs. The objective is to provide an introductory summary of where the field of gene therapy currently stands in the treatment of LSDs, and the directions the field is moving toward. Based on results in animal models, global gene transfer has the potential to profoundly alter the course of LSDs. Moreover, these newer approaches are scalable to large animals and presumably humans.

AB - Conceptually, lysosomal storage disorders (LSDs) are highly amenable to gene transfer therapies because they are monogenic and most of them can benefit from cross-correction. However, past gene transfer clinical trials for LSDs, utilizing focal delivery approaches to the brain for Batten disease and Canavan disease, have provided minimal therapeutic benefit to patients. Recent advancements in vector technology now allow for broad central nervous system and/or peripheral organ gene transfer via in vivo and ex vivo approaches, and the application of these technologies has shown considerable promise in small and large animal preclinical studies. Innate and adaptive immune responses pose a risk for the safety and efficacy of gene transfer in some human populations. This review discusses recent gene therapy advancements, other treatment options, and the risks and obstacles associated with the different therapeutic approaches for LSDs. The objective is to provide an introductory summary of where the field of gene therapy currently stands in the treatment of LSDs, and the directions the field is moving toward. Based on results in animal models, global gene transfer has the potential to profoundly alter the course of LSDs. Moreover, these newer approaches are scalable to large animals and presumably humans.

KW - Adeno-associated virus

KW - Central nervous system

KW - Gene therapy

KW - Lentivirus

KW - Lysosomal storage disease

UR - http://www.scopus.com/inward/record.url?scp=84930542694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930542694&partnerID=8YFLogxK

U2 - 10.1358/dof.2013.038.09.2038787

DO - 10.1358/dof.2013.038.09.2038787

M3 - Article

VL - 38

SP - 635

EP - 643

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 9

ER -